X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CG0070 (cretostimogene grenadenorepvec) is an investigational, intravesically delivered oncolytic immunotherapy. It is being evaluated for the treatment of Non-Muscle Invasive Bladder Cancer.
Lead Product(s): Cretostimogene Grenadenorepvec
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
The company intends to use the net proceeds to fund the research and development of Cretostimogene grenadenorepvec
Lead Product(s): Cretostimogene Grenadenorepvec
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $437.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 30, 2024
Details:
CG0070 (cretostimogene grenadenorepvec) is a GM-CSF agonist microorganism drug candidate, which is currently being evaluated for the treatment of Non-Muscle-Invasive Bladder Cancer unresponsive to bacillus calmette-guerin via intravesical liquid instillation.
Lead Product(s): Cretostimogene Grenadenorepvec
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
The proceeds will support the clinical programs in bladder cancer towards FDA approval including a Phase 3 study for CG0070 (cretostimogene grenadenorepvec) as a potential treatment for high-risk non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin.
Lead Product(s): Cretostimogene Grenadenorepvec
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Foresite Capital
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 02, 2023
Details:
CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): Cretostimogene Grenadenorepvec
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent which is being investigated in combination with keytruda® (pembrolizumab) in non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG).
Lead Product(s): Cretostimogene Grenadenorepvec,Pembrolizumab,Dodecyl Maltoside
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
CG0070 (cretostimogene grenadenorepvec) is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial in combination with keytruda for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): CG0070,Pembrolizumab,Dodecyl Maltoside
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication.
Lead Product(s): Engineered Oncolytic Adenovirus,Pembrolizumab
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
CG0070, is an intravesically delivered selective oncolytic immunotherapy agent that is currently in a Phase 3 trial for the treatment of BCG-unresponsive NMIBC.
Lead Product(s): CG0070,Pembrolizumab,Dodecyl Maltoside
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
The first poster presentation reports on efficacy and safety data from a global Phase 2 study of CG0070 in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the treatment of patients with Non-Muscle-Invasive Bladder Cancer.
Lead Product(s): CG0070,Pembrolizumab,Dodecyl Maltoside
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
